Faron Pharmaceuticals

Virtual drug company

Synergistics technologies

Drug candidates

News
FARON INITIATES PHASE I/II CLINICAL TRIAL IN UK TO TREAT ACUTE LUNG INJURY
US patent office has granted CLEVER-1 patent to Faron
TEKES FINANCES FARON'S ALI (Acute Lung Injury) PROGRAM WITH EUR 1.2 MILLION
Faron's scientific network has published in vivo animal efficacy data to treat acute lung injury with interferon-beta

Faron is a virtual drug company focusing to discovery and development of proprietary new compounds/use for:

 

• vasculopathies

• traumas

• inflammation

• metastasis